Haloperidol

Specifications

52-86-8CAS Number

200-155-6EC Number

4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-oneIUPAC Name

C21H23ClFNO2Chemical Formula

375.9 g/molMolecular Weight

haloperidol; 52-86-8; Serenace; Aloperidin; Eukystol; Serenase; Serenelfi; Linton; Aloperidolo; Galoperidol; Halopoidol; Brotopon; Halopal; Keselan; Ulcolind; Uliolind; Dozic; Pernox; Sernas; Sernel; Aldo; Einalon S; Sigaperidol; Peluces; Bioperidolo; Halosten; Haldol Solutab; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one; Haloperidolum; Fortunan; McN-JR-1625; R-1625; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; R 1625; 4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; 1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine; DTXSID4034150; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone; 4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone; 4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone; NSC-170973; NSC-615296; J6292F8L3D; NSC170973; 4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-; CHEBI:5613; DTXCID2014150; 4'-Fluoro-4-(4-hydroxy-4-p-chlorophenylpiperidino)butyrophenone; 4-(4-(para-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorobutyrophenone; Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-; 1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-; VESALIUM COMPONENT HALOPERIDOL; 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; gamma-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one; Butyrophenone, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro-; Kentace; Keselen; Dolpin; 4'-Fluoro-4-[4-hydroxy-4-(4'-chlorophenyl)piperidino]butyrophenone; gamma-[4-(p-chlorophenyl)-4-hydroxypiperidino]-p-fluorobutyrophenone; 4-[4-(para-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidyl)-1-(4-fluorophenyl)-butan-1-one; RefChem:5876; N05AD01; 200-155-6; Aloperidol; Halojust; Mixidol; Lealgin compositum; Aloperidon; 177716-59-5; C21H23ClFNO2; MFCD00051423; CHEMBL54; Haldol (TN); 4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone; MLS000028450; Butyrophenone, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one; NSC615296; CAS-52-86-8; NCGC00015500-10; Aloperidolo [DCIT]; Halidol; Halopidol; Pekuces; SMR000058303; Halol; Aloperidolo [Italian]; S1920; Haloperidolum [INN-Latin]; Neurodol; CHEMBL545608; NSC 170973; CCRIS 1630; HSDB 3093; SR-01000003076; EINECS 200-155-6; NSC 615296; BRN 0331267; UNII-J6292F8L3D; Fortunan;; Haloperidol RS; Epoxide resin,; Haloperidol CRS; Epoxy resin;; Haldol;; Picroside-III; Dozic;; Haloperidol, 1; Haloperidol, powder; Prestwick_250; Haloperidol (Haldol); Haloperidol [USAN:USP:INN:BAN:JAN]; PS14 - Haloperidol; Haloperidol (Standard); Spectrum_000861; Tocris-0931; starbld0018801; Epoxide resin, E-44; Opera_ID_446; HALOPERIDOL [MI]; 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;propionate(HCl); Prestwick0_000115; Prestwick1_000115; Prestwick2_000115; Prestwick3_000115; Spectrum2_001268; Spectrum3_000448; Spectrum4_000570; Spectrum5_000788; HALOPERIDOL [INN]; HALOPERIDOL [JAN]; Lopac-H-1512; HALOPERIDOL [HSDB]; HALOPERIDOL [USAN]; Biomol-NT_000035; GTPL86; Probes1_000255; Probes2_000296; H 1512; HALOPERIDOL [VANDF]; SCHEMBL8264; HALOPERIDOL [MART.]; Lopac0_000583; Oprea1_509923; BSPBio_000130; BSPBio_002096; HALOPERIDOL [USP-RS]; HALOPERIDOL [WHO-DD]; HALOPERIDOL [WHO-IP]; KBioGR_000980; KBioGR_002390; KBioSS_001341; KBioSS_002395; 5-21-02-00377 (Beilstein Handbook Reference); MLS001146904; BIDD:GT0128; DivK1c_000654; SPECTRUM1500325; SPBio_001236; SPBio_002069; McM-JR-1625; BPBio1_000144; BPBio1_001231; orb1224791; orb1311010; orb3141230; Haloperidol (JP18/USP/INN); Haloperidol - Bio-X trade mark; BDBM21398; Haloperidol, 1mg/ml in Methanol; HMS502A16; KBio1_000654; KBio2_001341; KBio2_002390; KBio2_003909; KBio2_004958; KBio2_006477; KBio2_007526; KBio3_001316; KBio3_002869; LNEPOXFFQSENCJ-UHFFFAOYSA-; HALOPERIDOL [ORANGE BOOK]; MSK7134; cMAP_000037; NINDS_000654; AC250; GLXC-06536; HALOPERIDOL [EP MONOGRAPH]; HALOPERIDOL [USP IMPURITY]; HMS1568G12; HMS1920D03; HMS2089M15; HMS2091J09; HMS2095G12; HMS2234P08; HMS3261F08; HMS3370H11; HMS3657I13; HMS3712G12; HMS5080H05; Pharmakon1600-01500325; HALOPERIDOL [USP MONOGRAPH]; Haloperidol 1.0 mg/ml in Methanol; STR04750; Tox21_110162; Tox21_300475; Tox21_500583; 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; BDBM50051276; CCG-36042; CCG-39111; EBC-03897; HALOPERIDOLUM [WHO-IP LATIN]; HY-14538R; NSC757054; STL417208; AKOS000280660; Haloperidol for system suitability CRS; Samarium(III) acetylacetonate xhydrate; Tox21_110162_1; AT13670; CS-1971; DB00502; FG32041; FH23734; Haloperidol for peak identification CRS; LP00583; NSC-757054; SDCCGSBI-0050565.P005; IDI1_000654; MRF-0000027; QTL1_000042; WLN: T6NTJ A3VR DF& DQ DR DG; NCGC00015500-01; NCGC00015500-02; NCGC00015500-03; NCGC00015500-04; NCGC00015500-05; NCGC00015500-06; NCGC00015500-07; NCGC00015500-08; NCGC00015500-09; NCGC00015500-11; NCGC00015500-12; NCGC00015500-13; NCGC00015500-14; NCGC00015500-15; NCGC00015500-16; NCGC00015500-17; NCGC00015500-19; NCGC00015500-24; NCGC00015500-31; NCGC00015500-32; NCGC00016234-01; NCGC00023875-02; NCGC00023875-04; NCGC00023875-05; NCGC00023875-06; NCGC00023875-07; NCGC00023875-08; NCGC00023875-09; NCGC00254503-01; NCGC00261268-01; AC-19691; BH166165; DA-74000; HY-14538; SY052276; SBI-0050565.P004; Haloperidol decanoate impurity, haloperidol-; SC 170973; AB00052008; EU-0100583; H0912; NS00010402; ST50319916; SW196557-4; C01814; D00136; H55351; M04089; VU0239704-10; AB00052008-21; AB00052008-22; AB00052008_23; AB00052008_24; Haloperidol; Haloperidol Decanoate EP Impurity G; L000288; Q251347; SR-01000003076-2; SR-01000003076-8; BRD-K67783091-001-04-8; BRD-K67783091-001-05-5; BRD-K67783091-001-25-3; BRD-K67783091-001-26-1; BRD-K67783091-003-03-6; BRD-K67783091-003-07-7; HALOPERIDOL DECANOATE IMPURITY G [EP IMPURITY]; SR-01000003076-11; Z1590789254; Haloperidol, European Pharmacopoeia (EP) Reference Standard; .gamma.-[4-(p-Chlorphenyl)-4-hydroxpiperidino]-p-fluorbutyrophenone; HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP IMPURITY]; Haloperidol, United States Pharmacopeia (USP) Reference Standard; .gamma.-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; 4-[4-(4-chlorophenyl)-4-hydroxypiperidyl]-1-(4-fluorophenyl)butan-1-one; Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl) -1-butanone; Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard; Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard; 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one; hydrochloride; InChI=1/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2; Poly[2-methoxy-5-(3 inverted exclamation marka,7 inverted exclamation marka-dimethyloctyloxy)-1,4-phenylenevinylene]; Poly[2-methoxy-5-(3,7-dimethyloctyloxy) phenylenevinylene-1,4-diyl], Mw 100,000-1000,000 by GPCSynonyms